New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 26, 2012
07:17 EDTAEGRAegerion label for Juxtapid looks favorable, says JPMorgan
JPMorgan views the label for Aegerion's Juxtapid as favorable and reiterates an Overweight rating on the stock after the FDA approved the drug. The firm upped its price target for shares to $30 from $28.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AEGR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use